SCHEMBL3924310

SCHEMBL3924310

CCOC(=O)c1c(NC(=O)NCC2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)sc2c1CCCC2

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.78
ALDH1A1 P00352 3/20 0.78
KDM4E B2RXH2 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
LMNA P02545 4/20 0.60
KMT2A Q03164 1/20 0.60
RXFP1 Q9HBX9 3/20 0.55
TP53 P04637 3/20 0.55
TLR2 O60603 6/20 0.55
USP2 O75604 1/20 0.50
CYP1A2 P05177 1/20 0.50
GAA P10253 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
RAD52 P43351 1/20 0.50
CNR2 P34972 1/20 0.50
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923527 0.94 KDM4E (0.70) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3914094 0.93 MAPT (0.67) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3918270 0.93 ALDH1A1 (0.70) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3923763 0.92 MAPT (0.66) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3911765 0.90 MAPT (0.63) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3923557 0.88 MAPT (0.61) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL6438499 0.88 MAPT (0.60) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3922717 0.86 MAPT (0.58) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3923638 0.85 TLR2 (0.62) MAPTALDH1A1KDM4ELMNAKMT2A
SCHEMBL6435792 0.84 SMN1; SMN2 (0.56) MAPTALDH1A1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298842-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PATO JANOS 2009-12-03 US claimed
US-20090018149-A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections AXXIMA PHARMACEUTICALS AG (DE) 2009-01-15 US claimed
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor VICHEM CHEMIE KFT (HU) 2004-09-02 US claimed
US-20090298842-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PATO JANOS 2009-12-03 US disclosed
US-20090018149-A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections AXXIMA PHARMACEUTICALS AG (DE) 2009-01-15 US disclosed
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor VICHEM CHEMIE KFT (HU) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298842-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PKLR, MASTL, BPGM MAPT 3062/4885ALDH1A1 4718/4885KDM4E 2651/4885
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PKLR, PKN1, PKMYT1 MAPT 2046/4885ALDH1A1 4655/4885KDM4E 2941/4885
US-20090018149-A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections STK4, SBK3, STK17B MAPT 2119/4885ALDH1A1 4146/4885KDM4E 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.